References – Preclinical Data
Brown Q.B., Baude A.S., Gilling K., Gianutsos G., Bahr B.A., and Parsons C.G. (2003) Memantine and
neramexane protect against semi-chronic 3-NP toxicity in organotypic hippocampal cultures. Soc
Neurosci 2003 (Poster)
Durlach J. (1990) Magnesium depletion and pathogenesis of Alzheimer's disease. Magnes Res 3:
217-8.
Durlach J., Durlach V., Bac P, Bara M, and Guiet-Bara A. (1994) Magnesium and therapeutics.
Magnes Res. 3-4: 313-28.
Fawcett W.J., Haxby E.J., and Male D.A. (1999) Magnesium: physiology and pharmacology. Br J
Anaesth. 83(2): 302-20.
Frankiewicz T., and Parsons C. (1999) Memantine restores long term potentiation impaired by tonic Nmethyl-D-aspartate (NMDA) receptor activation following reduction of Mg² + in hippocampal slices.
Neuropharmacology 38: 1253-1259
Fung M.C., Weintraub M., Bowen D.L. (1995) Hypermagnesemia. Elderly over-the-counter drug users
at risk. Arch Fam Med 4: 718-23.
Hallak M. (1998) Effect of parenteral magnesium sulfate administration on excitatory amino acid
receptors in the rat brain. Magnes Res 11: 117-31.
Hartnett K.A., Stout A.K., Rajdev S., Rosenberg P.A., Reynolds I.J., Aizenman E. (1997) NMDA
receptor-mediated neurotoxicity: a paradoxical requirement for extracellular Magnesium 2+ in Na+/Ca2+free solutions in rat cortical neurons in vitro. J. Neurochem. 68: 1836-45.
Helpern J.A., van de Linde A.M., Welch K.M., Levine S.R., Schultz L.R., Ordidge R.J., Halvorson H.R.,
Hugg J.W. (1993) Acute elevation and recovery of intracellular [Mg2+] following human focal cerebral
ischemia. Neurology 43: 1577-81.
Li L., Sengupta A., Haque N., Grundke-Iqbal I. and Iqbal K. (2004) Memantine inhibits and reverses
the Alzheimer type abnormal hyperphosphorylation of tau and associated neurodegeneration. FEBS
Letters 566: 261-269.
Kornhuber J., Bormann J., Retz W., Hübers M., and Riederer P. (1989) Memantine displaces [³H]MK801 at therapeutic concentrations in postmortem human frontal cortex. Eur J Pharmacol 166: 589-590
Ladner C.J. and Lee J.M. (1999) Reduced high-affinity agonist binding at the M(1) muscarinic receptor
in Alzheimer's disease brain: differential sensitivity to agonists and divalent cations. Exp. Neurol. 158:
451-8.
Misztal M, Frankiewicz T, Parsons CG, and Danysz W. (1996) Learning deficits induced by chronic
intraventricular infusion of quinolinic acid-protection by MK-801 and memantine. Eur J Pharmacol
296(1):1-8
Parsons C., Gruner R., Rozental J., Millar J., and Lodge D. (1993) Patch clamp studies on the kinetics
and selectivity of N-methyl-D-aspartate receptor antagonism by memantine. Neuropharmacology 32:
1337-1350
Reynolds I.J. (1998) Intracellular calcium and magnesium: critical determinants of excitotoxicity? Prog
Brain Res 116: 225-43.
Wenk G.L., Danysz W., and Mobley S.L. (1995) MK-801, memantine and amantadine show
neuroprotective activity in the nucleus basalis magnocellularis. Eur J Pharmacol 293(3):267-70
Zajaczkowski W., Frankiewicz T., Parsons C.G., and Danysz W. (1997) Uncompetitive NMDA receptor
antagonists attenuate NMDA-induced impairment of passive avoidance learning and LTP.
Neuropharmacology 36(7): 961-71
Zajaczkowski W., Quack G., and Danysz W. (1996) Infusion of (+)-MK-801 and memantine –
contrasting effects on radial maze learning in rats with endorhinal cortex lesion. Eur J Pharmacol 296:
239-246